Advertisement

Current Treatment Options in Infectious Diseases

, Volume 9, Issue 4, pp 389–402 | Cite as

Retreatment Options Following HCV Direct-Acting Antiviral Failure

  • Autumn Zuckerman
  • Cody A. Chastain
  • Susanna NaggieEmail author
Hepatitis C (J Raybould, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hepatitis C

Opinion Statement

Despite the excellent efficacy of direct-acting antivirals (DAA) for hepatitis C virus (HCV), treatment failures do occur. Until recently, retreatment decisions after DAA failure were influenced by the number of available agents, concerns about HCV drug resistance, and lack of data regarding retreatment. Recommended treatment approaches previously depended on limited clinical trials and expert opinion. In this article, we review the current state of the evidence for HCV retreatment after DAA failure. Based on recent clinical trial data, most patients who fail HCV treatment with DAA agents now have excellent retreatment options. While some patients may benefit from resistance testing after DAA therapy failure to select the optimal treatment and duration, newly approved salvage therapies are not significantly impacted by common mutations and have been approved by the Food and Drug Administration for HCV retreatment without regard for the presence of resistance-associated substitutions. While prior retreatment efforts were limited to longer courses of therapy, the addition of ribavirin, or novel combinations of approved therapies based on expert guidance, current DAA options make HCV retreatment in the DAA era more streamlined and evidence-based.

Keywords

Direct-acting antiviral (DAA) Hepatitis C virus (HCV) Relapse Retreatment Treatment 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Chastain reports research funding from Gilead Sciences, Inc. Dr. Naggie reports research funding from Gilead Sciences, Merck, Bristol-Myers Squibb, AbbVie, Janssen, and Tacere Therapeutics, Inc.

Funding Information

This work was supported by the National Institutes of Health (NIH) (1R01DK112295-01 to S. N.).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors. Dr. Naggie co-chairs the current HCV Guidance Panel AASLD/IDSA committee responsible for HCV guideline recommendations.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Shah ND, Fried MW. Treatment options of patients with chronic hepatitis C who have failed prior therapy. Clin Liver Dis. 2016;7(2):40–4.  https://doi.org/10.1002/cld.532.CrossRefGoogle Scholar
  2. 2.
    •• AASLD-IDSA. Retreatment of persons in whom prior therapy has failed. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed September 4, 2017. This guidance provides regular updates for the latest in recommendations regarding retreatment of HCV.
  3. 3.
    Buti M, Esteban R. Management of direct antiviral agent failures. Clin Mol Hepatol. 2016;22(4):432–8.  https://doi.org/10.3350/cmh.2016.0107.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Vermehren J, Susser S, Dietz J, von Hahn T, Petersen J, Hinrichsen H, et al. Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database. J Hepatol. 2016;64(2):S188.  https://doi.org/10.1016/S0168-8278(16)00128-8.CrossRefGoogle Scholar
  5. 5.
    Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504.  https://doi.org/10.1016/j.jhep.2015.09.011.CrossRefPubMedGoogle Scholar
  6. 6.
    Zepatier (TM) [package insert]. Kenilworth, NJ: Merck & Co., Inc.; 2016.Google Scholar
  7. 7.
    Mavyret(TM) [package insert]. North Chicago, IL: AbbVie, Inc.; 2017.Google Scholar
  8. 8.
    Harvoni (TM) [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2014.Google Scholar
  9. 9.
    Epclusa (TM) [package insert]. Fostor City, CA: Gilead Sciences, Inc.; 2016.Google Scholar
  10. 10.
    Vosevi (TM) [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2017.Google Scholar
  11. 11.
    • Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.  https://doi.org/10.1056/NEJMoa1316366. This study demonstrated the efficacy of LDV/SOF for retreatment of HCV GT1CrossRefPubMedGoogle Scholar
  12. 12.
    Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.  https://doi.org/10.1016/s0140-6736(13)62121-2.CrossRefPubMedGoogle Scholar
  13. 13.
    Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404.  https://doi.org/10.1016/S1473-3099(15)70050-2.CrossRefPubMedGoogle Scholar
  14. 14.
    Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564–72.  https://doi.org/10.1016/j.jhep.2015.04.009.CrossRefPubMedGoogle Scholar
  15. 15.
    • Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62(1):32–6.  https://doi.org/10.1093/cid/civ722. This study demonstrated the efficacy of EBV/GZP for retreatment of HCV GT1CrossRefPubMedGoogle Scholar
  16. 16.
    • Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):809–17.  https://doi.org/10.7326/M15-1014. This study demonstrated the efficacy of SOF/VEL for retreatment of HCV GT 1 and 3CrossRefPubMedGoogle Scholar
  17. 17.
    • Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.  https://doi.org/10.1056/NEJMoa1512610. This study further demonstrated the efficacy of SOF/VEL in HCV GT 1 and 3 as well as other genotypesCrossRefPubMedGoogle Scholar
  18. 18.
    •• Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66(2):389–97.  https://doi.org/10.1002/hep.29081. This study demonstrated the efficacy of GLE/PIB for retreatment of HCV GT1CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Poordad F, Stanislas P, Asatryan A, Buti M, Shaw D, Hezode C et al. MAGELLAN-1, Part 2: glecaprevir/pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. The International Liver Congress (EASL); April 22, 2017; Amsterdam, The Netherlands.Google Scholar
  20. 20.
    •• Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–46.  https://doi.org/10.1056/NEJMoa1613512. These studies demonstrated the efficacy of SOF/VEL/VOX for retreatment of all HCV genotypes after prior treatment failureCrossRefPubMedGoogle Scholar
  21. 21.
    Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017. [Epub ahead of print]  https://doi.org/10.1016/S1473-3099(17)30496-6.
  22. 22.
    Zeuzem S, Feld J, Wang S, Bourliere M, Wedemeyer H, Gane E et al. ENDURANCE-1: a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with glecaprevir/pibrentasivr (formerly ABT-493/ABT-530) in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis. The Liver Meeting (AASLD); November 11–15, 2016; Boston, MA.Google Scholar
  23. 23.
    Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17.  https://doi.org/10.1056/NEJMoa1512612.CrossRefPubMedGoogle Scholar
  24. 24.
    Kowdley KV, Colombo M, Aadeikis N, Mantry PS, Calinas F, Aguilar H et al. ENDURANCE-2: safety and efficacy of glecaprevir/pibrentasvir in hepatitis C virus genotype 2-infected patients without cirrhosis: a randomized, double-blind, placebo-controlled study. The Liver Meeting (AASLD); November 11–15, 2016; Boston, MA.Google Scholar
  25. 25.
    Wyles DL, Poordad F, Wang S, Alric L, Felizarta F, Kwo P et al. SURVEYOR-II, Part 3: efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or cirrhosis. The Liver Meeting (AASLD); November 11–15, 2016; Boston, MA.Google Scholar
  26. 26.
    Kwo PY, Badshah MB. Treatment of HCV in patients who failed first-generation PI therapy: a review of current literature. Curr Gastroenterol Rep. 2015;17(10):462.  https://doi.org/10.1007/s11894-015-0462-0.CrossRefPubMedGoogle Scholar
  27. 27.
    Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62(1):79–86.  https://doi.org/10.1002/hep.27826.CrossRefPubMedGoogle Scholar
  28. 28.
    Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263–71.  https://doi.org/10.1016/j.jhep.2017.03.039.CrossRefPubMedGoogle Scholar
  29. 29.
    Lawitz E, Kowdley K, Curry M, Reau N, Nguyen M, Kwo P, et al. High efficacy of sofosbuvir/velpatasvir plus GS-9857 for 12 weeks in treatment-experienced genotype 1-6 HCV-infected patients, including those previously treated with direct-acting antivirals. J Hepatol. 2016;64(2):S139–S40.  https://doi.org/10.1016/S0168-8278(16)01645-7.CrossRefGoogle Scholar
  30. 30.
    Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385(9986):2502–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15(9):1049–54.  https://doi.org/10.1016/S1473-3099(15)00157-7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Brown A, Hézode C, Zuckerman E, Graham RF, Amany Z, Stuart R et al. C-SCAPE: efficacy and safety of 12 weeks of grazoprevir +/− elbasvir +/− ribavirin in patients with HCV GT2, 4, 5, or 6 infection [Abstract P0771]. The International Liver Congress (EASL); April 22–26, 2015; Vienna, Austria.Google Scholar
  33. 33.
    Abergel A, Asselah T, Metivier S, Loustaud-Ratti V, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16(4):459–64.CrossRefPubMedGoogle Scholar
  34. 34.
    AASLD-IDSA. Management of unique populations with HCV infection. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed September 4, 2017.

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Autumn Zuckerman
    • 1
  • Cody A. Chastain
    • 2
  • Susanna Naggie
    • 3
    Email author
  1. 1.Department of Pharmacy, Vanderbilt Specialty PharmacyVanderbilt University Medical CenterNashvilleUSA
  2. 2.Division of Infectious DiseasesVanderbilt University Medical CenterNashvilleUSA
  3. 3.Duke Clinical Research InstituteDuke University School of MedicineDurhamUSA

Personalised recommendations